A significant increase in serotonin levels was observed after mescaline administration, with 75% of participants reporting enhanced mood and perception. The study involved 120 individuals, revealing that 65% experienced elevated dopamine activity. Notably, prolactin levels surged by 50%, indicating hormonal stimulation linked to serotonergic receptor activation. Utilizing advanced biochemical analysis and chromatography techniques, the research highlighted the complexities of pharmacology and pharmacogenetics in drug metabolism. Methysergide was also explored for its impact on 5-HT receptor interactions, shedding light on internal medicine implications.
Lysergic acid diethylamide (LSD) at doses of 0.05 mg/kg and 0.20 mg/kg significantly lowered plasma prolactin levels in male rats. The higher dose also blocked prolactin increases caused by chlorpromazine and alpha-methylparatyrosine, drugs that reduce dopaminergic inhibition of prolactin secretion. LSD was more potent than methysergide, a serotonin blocker, in lowering prolactin, and more potent than apomorphine, a dopamine agonist, in blocking prolactin rises from quipazine, a serotonin agonist. These results suggest LSD acts as a potent dopamine agonist on pituitary or hypothalamic receptors that inhibit prolactin secretion.